

TiGenix publishes transparency notifications pursuant to Article 14 of the Law of May 2, 2007

Leuven (Belgium) – March 22, 2016, 19:00h CET – TiGenix NV (Euronext Brussels: TIG) publishes today two transparency notifications pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions.

Summary of the notifications

It concerns the following notifications:

- Notification dated March 15, 2016 by BNP Paribas Investments Partners SA, following the acquisition of shares on March 10, 2016, after which BNP Paribas Investments Partners SA (through its subsidiaries BNP Paribas Investments Partners UK Ltd and BNP Paribas Investments Partners Belgium SA) held 6,650,503 shares (3.75%); and
- Notification dated March 17, 2016 by Novartis AG/Novartis Bioventures Ltd, following the passive downward crossing below the 3% threshold on March 14, 2016.

Content of the notification by BNP Paribas Investments Partners SA

Date of the notification: March 15, 2016.

Reason of the notification: acquisition of shares.

Person subject to the notification requirement: BNP Paribas Investments Partners SA, TSA 47000, 75318 Paris Cedex 09, France, who is a parent undertaking/controlling person.

Date on which the threshold was crossed: March 10, 2016.

Threshold that was crossed: 3%.

Denominator: 177,304,587.

Details of the notification: following the acquisition of shares, the shareholdings were as follows:

- BNP Paribas Investments Partners SA held 0 shares (0%),
- BNP Paribas Investments Partners UK Ltd held 4,544,147 shares (2.56%), and
- BNP Paribas Investments Partners Belgium SA held 2,106,356 shares (1.19%)
- **Total:** 6,650,503 shares (3.75%).

Chain of controlled undertakings through which the holdings are effectively held: BNP Paribas Investments Partners UK Ltd and BNP Paribas Investments Partners Belgium SA are controlled by BNP Paribas Investments Partners SA, which in turn is controlled by BNP Paribas SA which benefits from an exemption to aggregate its participations with the participations of its subsidiaries investment companies pursuant to article 21 of the Royal Decree of February 14, 2008 regarding the publication of major holdings.



Additional information: BNP Paribas Investments Partners UK Ltd and BNP Paribas Investments Partners Belgium SA are investment companies who exercise voting rights in a discretionary way.

Content of the notification by Novartis AG/Novartis Bioventures Ltd

Date of the notification: March 17, 2016.

Reason of the notification: passive downward crossing of the lowest threshold.

Person subject to the notification requirement: related companies Novartis AG (with address at Lichtstrasse 35, 4056 Basel, Switzerland) / Novartis Bioventures Ltd (with address at Front Street 131, Hamilton, HM, 12 Bermuda).

Date on which the threshold was crossed: March 14, 2016.

Threshold that was crossed: 3%.

Denominator: 202,304,587.

Details of the notification: in the previous transparency notification by Novartis AG / Novartis Bioventures Ltd, the following shareholdings were notified:

- Novartis AG held 0 shares (0%), and
- Novartis Bioventures Ltd held 5,534,905 shares
- **Total:** 5,534,905 shares.

Chain of controlled undertakings through which the holdings are effectively held: Novartis AG controls Novartis Bioventures Ltd.

This press release and the above-mentioned transparency notifications can be consulted on our website:

- press release: <http://www.tigenix.com/en/pages/11/2016>;
- notifications: <http://www.tigenix.com/en/page/26/shareholders>.

For more information:

TiGenix NV
Claudia D'Augusta
Chief Financial Officer
T: +34 91 804 92 64
claudia.daugusta@tigenix.com

About TiGenix

TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells. Two products from the adipose-derived stem cell technology platform are currently in clinical development. Cx601 is in Phase III for the treatment of complex perianal fistulas in Crohn's disease patients. Cx611 has completed a Phase I sepsis challenge trial and a Phase I/II trial in rheumatoid arthritis. Effective July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product, AlloCSC-01, is currently in a Phase II clinical trial in acute myocardial infarction (AMI). In addition, the second product candidate from the cardiac stem cell-based platform acquired from Coretherapix, AlloCSC-02, is being developed in a chronic indication. TiGenix also developed ChondroCelec, an autologous cell therapy product for cartilage repair of the knee, which was the first Advanced Therapy Medicinal Product (ATMP) to be approved by the European Medicines Agency (EMA). From June 2014,

TiGENIX

the marketing and distribution rights of ChondroCelect were exclusively licensed to Sobi for the European Union (except for Finland, where it is distributed by the Finnish Red Cross Blood Service), Norway, Russia, Switzerland and Turkey, and the countries of the Middle East and North Africa. TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain).